Management of chronic obstructive pulmonary disease (COPD), a complex, heterogeneous disease, has been complicated by new recommendations that incorporate novel escalation strategies with dual bronchodilation treatments. Fixed-dose combination (FDC) dual bronchodilation, consisting of a long-acting ß agonist (LABA) combined with a long-acting muscarinic antagonist (LAMA), has emerged as an effective strategy for patients who require escalation beyond LABA or LAMA monotherapy, with an emphasis on outcomes beyond lung function, including reducing exacerbations. For patients who require escalation beyond LAMA/LABA or other dual therapies, there is now a fixed-dose, once-daily triple therapy (LAMA/LABA/inhaled corticosteroid [ICS]) inhaler. Despite updated recommendations, limited practical guidance on individualizing therapy or identifying patients who may benefit from treatment escalation (ie, escalating from mono- to dual bronchodilation therapy or adding an ICS/escalating to triple therapy) exists. In addition, lack of knowledge of appropriate COPD inhaler choice/use and self-management strategies persists, precluding optimal therapeutic benefit and clinical outcomes. This archived symposium activity will feature 3 experts in COPD, who will review and discuss the clinical science behind dual bronchodilation therapy, advances in triple therapy, and the new COPD recommendations, as well as implementation of practical individualized treatment and inhaler strategies for patients with COPD.